Transdermal deferoxamine administration improves excisional wound healing in chronically irradiated murine skin

• DOI: 10.1186/s12967-022-03479-4
• Publication Date: 2022-06-17T10:04:26Z
• Authors: Hendrik Lintel; Darren B. Abbas; Christopher V. Lavin; Michelle Griffin; Jason L. Guo; Nicholas Guardino; Andrew Churukian; Geoffrey C. Gurtner; Arash Momeni; Michael T. Longaker; Derrick C. Wan
• Keywords: Skin repair

Radiation-induced skin injury is a well-known risk factor for impaired wound healing. Over time, the deleterious effects of radiation on produce fibrotic, hypovascular dermis poorly suited to Despite increasing understanding underlying pathophysiology, therapeutic options remain elusive. Deferoxamine (DFO), an iron-chelating drug, has been shown in prior murine studies ameliorate radiation-induced as well improve healing outcomes various pathologic conditions when administered transdermally. In this preclinical study, we evaluated deferoxamine chronically irradiated skin.Wild-type mice received 30 Gy irradiation their dorsal and were left develop chronic fibrosis. Stented excisional wounds created skin. Wound compared across 4 experimental conditions: DFO patch treatment, vehicle-only untreated wound, nonirradiated wounds. Gross closure rate, perfusion, scar elasticity, histology, nitric oxide assays conditions.Relative vehicle wounds, accelerated reduced frequency failure augmented perfusion throughout upregulated angiogenesis levels observed Histology revealed increased thickness, collagen density, improved fiber organization more closely resemble likely contributing elasticity. Lastly, inducible synthase production early wounds.Deferoxamine treatment presents potential avenue through which target patients following radiotherapy.